

Highlights

- Best Trades of the Week
- Tech Mahindra Q4 profit falls 17.4% to Rs 1,081.4 crore, revenue grows at 0.9%
- Mphasis shares jump 6% after Blackstone commits up to \$2.8 billion to acquire controlling stake in firm
- Natco Pharma seeks approval for COVID drug candidate Molnupiravir; shares jump 7%

Tech Mahindra Q4 profit falls 17.4% to Rs 1,081.4 crore, revenue grows at 0.9%

Software services company Tech Mahindra on April 26 has reported a 17.4 percent sequential decline in consolidated profit at Rs 1,081.4 crore for the quarter ended March 2021. The profit in the previous quarter was at Rs 1,309.8 crore.

Consolidated revenue for the quarter at Rs 9,729.9 crore grew by 0.9 per cent over Rs 9,647.1 crore in December quarter.

The numbers missed analysts' expectations as profit was estimated at Rs 1,313 crore on revenue of Rs 9,830 crore for the quarter, according to an average of a CNBC-TV18 analysts poll.

IT services business registered a 1 percent sequential growth in revenue at Rs 8,673 crore but the BPO segment revenue was almost flat at Rs 1,056.9 crore in Q4FY21 against Rs 1,056.6 crore in the previous quarter.

Revenue in dollar terms grew by 1.6 percent sequentially to \$1,329.6 million and the revenue growth stood at 0.7 percent QoQ in constant currency terms, which missed CNBC-TV18 poll estimates of 2.7 percent and 2 percent, respectively. "Our continued focus on cutting-edge technologies has expanded client engagement with large deal wins this quarter. We are witnessing a strong demand acceleration and are committed towards delivering a next-level human-centered experience of the future. The health and wellness of our

associates and community, at large, continues to be our prime focus, as we navigate through this pandemic together," said CP Gurnani, Managing Director & Chief Executive Officer.

Source:moneycontrol.com

Best Trades of the Week

19 April 2021 -

20 April 2021 Profit of Rs. 129,846

21 April 2021 HOLIDAY

22 April 2021 Profit of Rs. 266,110

23 April 2021 Profit of Rs. 36,248

Indian market witnessed a volatile week as bears took control pushing the Nifty lower for the third consecutive day in a row below 14,400, but small & midcap stocks outperformed on a relative basis.

The S&P BSE Sensex, and Nifty50 fell by about 2 percent each while the S&P BSE Midcap index was down by 1 percent while the S&P BSE Smallcap index closed flat with a negative bias for the week ended April 23. In this highly volatile week as well, one of our traders made a profit of Rs. 266,110 on 22 April 2021, the highest of all other days in a week.

Making a consistent profit should be the ideal approach rather than looking at the percentage of profits. Yogeshwar sir always teach one important rule of the stock market which is "Always work on reducing your risk and never allow yourself to take a big loss."

If you want to stay in the stock market game,

then you should work on making a consistent profit and reducing your risk. Risk management is the key to success here. I believe, people who don't follow proper risk management, always find themselves in the struggle. No doubt, you would have made a big profit some days. But the real challenge is to maintain that kind of profits everyday day. If you are making Rs. One lakh in a day and losing the same on other days. You are not working as a professional trader. I can assume this sort of profit-making is through gambling.

What we have learned at Pathfinders Trainings, you can see the results of that learning by looking at the profits made by professional

traders. Every trade is good, even you make less profit. But working on not making big losses in the market should be our priority. If we have the capital to play in the market, our small loss can be turned into a small profit and with consistency, into a big profit.

Natco Pharma seeks approval for COVID drug candidate Molnupiravir; shares jump 7%

Natco Pharma share price jumped over 7 percent intraday on April 26 after the company said it has applied for the emergency approval of Molnupiravir capsules for COVID-19 treatment.

" has applied to the Central Drugs Standard Control Organization (CDSCO) in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 positive patients," company said in the release to the exchanges.

"Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication," the company said in a statement.

Source:moneycontrol.com

Free Stock Market Webinar

Friday (April 30, 2021)

Register today to attend using the following link:

<https://www.pathfinderstrainings.com/training/freetrainings.aspx>

PATHFINDERS TRAININGS

Let's talk, Don't hesitate to reach out with the contact information below,

Get in Touch

Pathfinders Trainings

Hiranandani

Thane (West), Mumbai, Maharashtra

400610, India

pathfinders@pathfinderstrainings.com

M. 9022330009

